Intercell announces Phase I results on its Vaccine Enhancement Patch (VEP) with Pandemic Influenza antigens
Intercell will focus its future patch strategy on partnering and out-licensing based on an updated target product profile
19-Sep-2012 -
Intercell AG announced the results from a Phase I study investigating Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a heat-labile toxin from E. coli) in combination with an IM administration of an A/H5N1 antigen supplied by GSK.This trial follows earlier Phase I and ...
influenza
Intercell
pandemic influenza
+1